Intellectual Property India Publishes Patent Application for Design, Synthesis, Invitro Evaluation Of Fused Imidazoquinolone Trione Hybrids As Potential Inhibitors Of Jka2 Targets As Anticancer Drugs

MUMBAI, India, June 26 -- Intellectual Property India has published a patent application (202641072129 A) filed by G Buela Priyanka; Dr Naga Venkata Indhira Devi Jajula; Dr. Perla Swathi; Dr Yadala Prapurna Chandra; Shaik Asma Parveen; Dr A Vyshnavi; Yajerla Ratna Kumari; Dr Ravi Kumar Vakkalagadda; Prathibha G S; and Dr Sandhya Kota on June 10, 2026, for Design, Synthesis, Invitro Evaluation Of Fused Imidazoquinolone Trione Hybrids As Potential Inhibitors Of Jka2 Targets As Anticancer Drugs.

Inventors include G Buela Priyanka; Dr Naga Venkata Indhira Devi Jajula; Dr. Perla Swathi; Dr Yadala Prapurna Chandra; Shaik Asma Parveen; Dr A Vyshnavi; Yajerla Ratna Kumari; Dr Ravi Kumar Vakkalagadda; Prathibha G S; and Dr Sandhya Kota.

The application for the patent was published on June 19, 2026, under issue no. 25/2026.

Abstract: Some novel compounds 6-(4-chlorophenyl)-5,6-dihydro-4H-benzo[g]imidazo[4,5,1-ij]quinolone-2,4,7-trione derivatives are constructed on a hybrid structure combining the imidazo-quinolone trione moieties which are designed and synthesized to get the final compounds and confirmed from the spectral charecterisation by H1 NMR, C13 NMR, MASS and IR spectras and were tested for the pharmacological activity against the blood cancer cell lines K562 by the MTT assay method of which the compounds exhibited better IC50 values. All the synthesized compounds showed mild to moderate anticancer activity against the K562 cell lines. The compounds elicited better activities against the cancer cell lines targeting JKA2 receptor proteins of which the compounds 5b have efficient IC50 values of 6.54uM when compared to the reference compound . And the compound 5b, 5a and 5g exhibited the IC50 values of 6.54 uM, 7.83 uM and 9.72 uM. All the compounds showed IC 50 values ranging from 6.54 uM -64.09 uM which are very good values for exhibiting efficient anticancer activities. And the studies revealed that the synthesized compounds are the efficient moieties considered for the development of lead molecules for the drug developement.

Disclaimer: Curated by HT Syndication.